All news (page 84)

19 March 2026

EU invests €330m in fusion and nuclear R&D and skills

Work Programme funds fusion-to-grid R&D, a PPP, startups, skills and facilities; supports fission research on waste, safety, materials, medical isotopes and talent mobility.
19 March 2026

FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial

Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
19 March 2026

MOL aligns directors' term expirations to April

Director György Bacsa resigns effective 30 Apr 2026; board proposes re-election for 1 May 2026–30 Apr 2031 at the AGM on 10 Apr 2026, aligning all board terms to April.
19 March 2026

QatarEnergy: Missile strikes cut LNG export capacity 17%, $20bn annual loss

Missile strikes at Ras Laffan damaged LNG Trains 4 & 6; repairs may take 3–5 years with force majeure on contracts. Pearl GTL offline ≥1 year; condensate, LPG, naphtha and helium production affected.
19 March 2026

Genmab: Board constituted; grants RSUs and warrants to employees

Deirdre P. Connelly named Chair; Pernille Erenbjerg Deputy Chair. 5,213 RSUs (DKK1,645/share) and 4,485 warrants (exercise DKK1,645; Black‑Scholes value DKK530.62). Vesting in 3 years.
19 March 2026

Aptar’s Unidose Nasal Powder System Used in ENA Respiratory Phase II INNA‑051 Study

Powder nasal device used in a Phase II trial of a once-weekly spray to assess safety, tolerability and reduction of symptomatic infections; device offers single-dose precision and moisture protection.
19 March 2026

OMV and ADNOC delay BGI listing, exchange offer and capital increase to 2027

Timing aligned to a 2027 capital increase; 2026 dividend cut will lower parent payout by ~€0.6–0.7/sh (payout USD250m vs USD500m). Further support measures possible.
19 March 2026

Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss

STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
19 March 2026

Kemira board elects chair, vice chair and committee members

Organizing meeting set Audit and Personnel & Remuneration committees and their chairs; all board members independent except Annika Paasikivi, who is linked to major shareholder Oras Invest.
19 March 2026

ADNOC and OMV progress formation of Borouge Group International AG

New asset-usage deal for Borouge 4 secures USD 400m cumulative net profit over three years, ~10% EPS accretion, adds 1.5Mt cracker/1.4Mt PE and lifts combined capacity to 13.6Mt.
19 March 2026

Technip Energies: Gulf region update

Monitoring Gulf after attacks on Riyadh refinery and Ras Laffan LNG; no injuries or damage at operated sites; precautionary shelter-in-place and relocations; coordinating with authorities.
19 March 2026

Croda opens Dahej manufacturing facility in India

New Dahej plant boosts supply for Life Sciences, Consumer Care and Industrial sectors; uses low‑carbon power, ZLD, RSPO feedstocks, advanced ops, safety focus and women-led packaging.
19 March 2026

GSK: Lynavoy (linerixibat) FDA-approved for cholestatic pruritus in PBC

FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.
19 March 2026

Iberdrola hits 11 GW U.S. generation capacity

Nearly 100 U.S. facilities across 25 states, capacity meets >7M Americans; added 850 MW recently. Plans €16B investment (2025-28) for grids and new generation.
19 March 2026

Lilly's retatrutide lowers A1C up to 2% and weight up to 16.8% in Phase 3 T2D trial

Phase 3 TRANSCEND-T2D-1 met primary and key secondary endpoints at 40 weeks; weight loss continued without plateau. Common AEs: GI events; mild dysesthesia; improved lipids and systolic BP.
19 March 2026

Eni proposes €1.5bn buyback program and cancellation of purchased treasury shares

Board seeks shareholder approval May 6 to buy up to 303M shares through Apr 2027; up to 5.1M for LTIP; purchases limited to ±10% of prior session price; currently holds 86.8M (2.9%).
19 March 2026

Eni reorganises Plenitude ownership, prompting deconsolidation

Raise ~€1.5bn via non‑pro rata issue (pre‑money €10.75bn). New joint control; major holder ~65%. Funds to back 15 GW and 15M customers by 2030. Subject to approvals.
19 March 2026

Eni 2026–2030 Plan

Consistent strategy: strong E&P project pipeline driving 3-4% production growth to 2030, self-funding Transition units, CFFO rising to €17bn, €40-45bn FCF 2026-30, lower gearing and higher payouts.
19 March 2026

Heidelberg Materials to reduce clinker production at Skövde plant

Skövde will shift from clinker making to cement-only from 2027, sourcing clinker mainly from Slite due to weak construction demand; consultations on organisational changes will follow.
19 March 2026

WACKER unveils BELNEXT bio-based ingredients at in-cosmetics Global 2026

TAL 1840 M: theanine-based cationic emulsifier (fermentation-made, biodegradable) for hair. EMO FH2: fermentation-made nonpolar emollient—stable, improves spread, combability and pigment dispersion
19 March 2026

Honeywell launches AI-powered Experion Operations Assistant

AI control-room tool Experion Operations Assistant uses historical and real-time data to forecast alarms (5-10 min ahead in pilots), integrates with Experion PKS and advises operators.
19 March 2026

Clariant opens pharma-grade PEG manufacturing plant in Texas

GMP-compliant excipient production strengthens supply-chain resilience, shortens lead times, and improves continuity and traceability for pharma customers across North & Latin America.
19 March 2026

EnviTec Biogas and LIQVIS expand Bio‑LNG network

Bio-LNG: low-emission, price-stable heavy-truck fuel—up to 1,700 km range, ~15-min refuel, <€1/kg; made from local organic feedstocks and rolled out via expanding station network
19 March 2026

BASF opens world's first industrial 3D‑printed catalyst plant in Ludwigshafen

X3D 3D-printed catalysts offer geometries that cut pressure drop, increase active surface and throughput, lower energy use; proven in customer plants.
19 March 2026

bp to sell Gelsenkirchen refinery to Klesch Group

Sale of Gelsenkirchen refinery raises structural cost-cut target by ~$1bn to $6.5-7.5bn by 2027, strengthens balance sheet, is free-cash-flow accretive; 12Mtpa, ~1,800 staff; close H2 2026.
19 March 2026

Elkem rated BBB- by Scope; Outlook Negative

Weak 2025 results and limited deleveraging from the Silicones divestment; company plans cost and debt reductions to restore investment-grade metrics.
19 March 2026

Plastic Energy powers start-up of TotalEnergies' Grandpuits advanced recycling plant

New 15,000 t/yr advanced recycling plant now producing TACOIL from hard-to-recycle plastics, feeding petrochemical sites to make high-quality, food- and medical-grade plastics.
19 March 2026

Hungary refuses to recognize Croatian convictions against MOL Group CEO

Budapest court ruled Croatian convictions incompatible with Hungarian law, citing fair-trial and defense breaches, after ICSID/UNCITRAL found no corruption and INTERPOL lifted the warrant
19 March 2026

Equinor creates two business areas to sharpen market focus

Establishes two units: midstream/processing/infrastructure to secure safe, efficient onshore operations; and a market/trading unit to capture value from products and data. New org operational early 2027.
19 March 2026

Equinor Annual Report 2025

Record production and strong cash results in 2025; safety improved; adjusted operating income $27.6B; production 2,137 mboe/d; renewables +25%; emissions −34% since 2015.

← Previous Next →